Neurocrine Biosciences Announces the Start of Phase II Study of Elagolix in Uterine Fibroids

Neurocrine Biosciences, Inc. NBIX today announced that Abbott has started a Phase II clinical trial to evaluate elagolix, a next-generation Gonadotropin Releasing Hormone (GnRH) Receptor Antagonist, in the treatment of uterine fibroids. The initiation of this trial triggered a $10 million milestone payment from Abbott ABT to the Company.